Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease. Issue 11 (18th October 2005)

• Record Type: Journal Article
• Authors: Kitamura, M; Kitaichi, N; Takeuchi, M; Kitamei, H; Namba, K; Yamagishi, S-i; Iwabuchi, K; Onoé, K; Ohno, S
• Is Part Of: British journal of ophthalmology. Volume 89:Issue 11(2005)
• Page Start: 1407
• Page End: 1409
• Publication Date: 2005-10-18
• Subjects: AGEs, advanced glycation end products -- EAAU, experimental autoimmune anterior uveitis -- ELISA, enzyme linked immunosorbent assay -- RAGE, receptor for AGE -- VKH, Vogt-Koyanagi-Harada; Vogt-Koyanagi-Harada disease -- advanced glycation end products -- melanocyte; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1136/bjo.2005.072678
• Languages: English
• ISSNs: 0007-1161

Abstract

Abstract : Background/aims: Advanced glycation end products (AGEs) are considered to act as mediators of both age related pathologies and diabetic complications. It was recently reported that glyceraldehyde derived AGE (AGE-2) has a strong biological effect on various diseases. The aim of this study was to investigate the serum AGE-2 levels in Vogt-Koyanagi-Harada (VKH) disease. Methods: Sera were obtained from 31 patients with active VKH. 20 of these 31 patients were treated with systemic corticosteroids. As controls, 33 healthy volunteers were also examined. The serum AGE-2 levels were determined with a competitive enzyme linked immunosorbent assay using AGE-2 polyclonal antibody. Results: The mean AGE-2 level in the sera of patients with VKH disease was 4.91 (SD 2.23) U/ml, which was significantly lower than that of the healthy control subjects (8.32 (2.94), p<0.001). The average serum AGE-2 level significantly increased to 13.49 (2.17) U/ml after the patients were treated with systemic corticosteroids (p<0.001). Conclusions: These results suggest that AGE-2 may be involved in the onset of VKH disease.